35 years old|0
    female|0
    Hodgkin lymphoma|0
    nodular sclerosis subtype|0
    primary refractory HL|0
    admitted to the hospital|0
    generalized pruritus|0
    atopic dermatitis|0
    corticoid-based therapy|0
    laterocervical lymphadenopathies|0
    night fever|0
    intense sweating|0
    supra-diaphragmatic lymphadenopathies|0
    infra-diaphragmatic lymphadenopathies|0
    abdominal masses|0
    lymphadenopathy biopsy|0
    NS classic HL|0
    stage IIIB HL|0
    International Prognostic Score 2|0
    ABVD chemotherapy regimen|0
    partial response|-5520
    early relapse|-5520
    primary refractory to ABVD|-5520
    ESHAP salvage chemotherapy regimen|-5520
    no response|-5520
    GemOx chemotherapy regimen|-5520
    neutropenia grade 4|-5520
    thrombocytopenia grade 4|-5520
    dose-intensity failures|-5520
    chemotherapy discontinuation|-5520
    radiotherapy consolidation|-5520
    HL progression|-5520
    IFE chemotherapy regimen|-5520
    stable disease|-5520
    watch-and-wait policy|-5520
    localized progression with radiotherapy|-5520
    transient partial responses|-5520
    new mass in D8â€“D9|-5520
    medullar compression syndrome|-5520
    HL relapse|-5520
    radiotherapy|-5520
    GemOx chemotherapy|-5520
    partial response|-5520
    new progression in left cervical nodes|-5520
    new progression in axillary nodes|-5520
    watch-and-wait policy|-5520
    symptomatic disease progression|-5520
    PET/CT confirmation|-5520
    bendamustine 90 mg/m2|-5520
    disease stability|-5520
    HL progression|-5520
    significant B symptoms|-5520
    worsening clinical status|-5520
    celecoxib 200 mg every 12 hours|0
    lenalidomide 20 mg|0
    compassionate use treatment|0
    unremarkable toxicity|0
    excellent tolerance|0
    complete response|0
    interim CT/PET after three cycles|0
    final CT/PET after six cycles|0
    CT scan in August 2015|0
    celecoxib maintenance 200 mg/12 hours|0
    anemia due to gastrointestinal bleeding|0
    celecoxib discontinuation|0
    disease relapse|0
    supra-abdominal adenopathies|0
    infra-abdominal adenopathies|0
    hepatic lesions|0
    splenic lesions|0
    negative biopsies|0
    asymptomatic situation|0
    celecoxib restarted 200 mg every 12 hours|0
    disease progression to ascites|0
    paracentesis|0
    persistent HL|0
    brentuximab vedotin|0
    intensive care admission|0
    sepsis|0
    fatal outcome|0
    <|eot_id|>